Levonic (Levofloxacin)

Levofloxacin inhibits two essential bacterial enzymes, DNA gyrase and topoisomerase IV. These enzymes are required for DNA supercoiling and replication. By blocking their activity, levofloxacin prevents bacterial DNA synthesis, leading to bacterial cell death and clearance of the infection.

The dosage of Levonic is individualized by the prescriber according to the type and severity of infection, patient weight, renal function, and other clinical factors. Only a qualified healthcare professional can determine the appropriate dose and duration for each patient.

Levonics is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss risks and benefits with their healthcare provider before using the product.

To request Levonic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Levonics (levofloxacin) offers a broad spectrum of activity against Gram‑negative and Gram‑positive bacteria and is often preferred for its once‑daily dosing and high bioavailability compared with older fluoroquinolones such as ciprofloxacin. However, choice of therapy depends on local resistance patterns, patient factors, and specific infection site.

Levonics should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Proper storage maintains drug stability and potency until administration.

Levonics is supplied as an intravenous solution and is administered by a qualified healthcare professional via slow IV infusion. The infusion rate and duration are determined by the prescribing clinician based on the infection being treated and patient tolerance.

Serious adverse events include tendon rupture (especially Achilles tendon), QT interval prolongation leading to potentially life‑threatening arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored closely for any signs of these conditions.

Levonics is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and patients taking other medications that significantly prolong the QT interval. Clinicians must assess each patient’s medical history before prescribing.